Volume 5 Supplement 1

23rd European Workshop for Rheumatology Research

Open Access

Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response

  • H Marotte1 and
  • P Miossec1
Arthritis Res Ther20035(Suppl 1):49

DOI: 10.1186/ar679

Received: 14 January 2003

Published: 24 February 2003

Background

Infliximab is an anti-tumor-necrosis-factor (anti-TNF) antibody used for the treatment of rheumatoid arthritis.

Objective

To clarify heterogeneity in patient response, a bioassay was established to measure functional circulating tumor necrosis factor (TNF).

Results

Culture of TNF activated synoviocytes with plasma samples before and after infliximab treatment showed an increased production of IL-6 that was strongly reduced by treatment. This pattern was associated with a good clinical response, and bioactive TNF levels detected with this bioassay were correlated with TNF levels measured by ELISA. This was not observed in patients with a poor response. The functional circulating bioactive TNF was significantly (P < 0.001) more elevated in subset with a good biological response than bad responders. No correlation was observed with levels of soluble receptors.

Conclusion

This result suggests the importance of systemic bioactive TNF in such response.

Authors’ Affiliations

(1)
Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Hérriot

Copyright

© The Author(s) 2003

Advertisement